Open access peer-reviewed chapter

Cytotoxic Effect and Mechanisms from Some Plant-Derived Compounds in Breast Cancer

Written By

Elvia Pérez-Soto, Cynthia Carolina Estanislao-Gómez, David Guillermo Pérez-Ishiwara, Crisalde Ramirez-Celis and María del Consuelo Gómez-García

Submitted: January 30th, 2019 Reviewed: May 31st, 2019 Published: August 6th, 2019

DOI: 10.5772/intechopen.87177

Chapter metrics overview

1,147 Chapter Downloads

View Full Metrics


Breast cancer (BrC) is a major health problem in women all around the world. A growing knowledge about these alterations and their associated molecular signaling pathways offers opportunities for therapeutic strategies; chemotherapy is one of the most utilized treatments; however, because of the adverse side effects and multidrug resistance that patients may present, there has been great advancement in search of new alternatives as the use of plant-derived natural compounds. This review describes information on the progress and development of cytotoxic compounds against BrC belonging to the families of flavonoids, terpenes, and alkaloids that through in vitro and in vivo studies have demonstrated to induce cellular death mainly through apoptosis, activating the intrinsic pathway. The in vitro IC50 and the in vivo EC50 dose-response relationship can vary depending on various factors, including the choice of cell line and/or the model used. Also, the association of some of these compounds with nanoparticles or paclitaxel with antibodies has clearly shown a potential improvement in its effect. The clinical studies that are being conducted with some of them show promising results; however, it is necessary to continue with the effort to develop new and more effective drugs against different types of BrC.


  • breast cancer
  • cytotoxic agents
  • natural products
  • in vitro model
  • in vivo model
  • flavonoids
  • terpenoid
  • alkaloids
  • nanoparticles

1. Breast cancer (BrC)

Cancer is the uncontrolled and unregulated growth of cells that generally invade and destroy normal cells [1]. Breast cancer [BrC] is the deadliest malignancy in women worldwide and also an important public health problem being the second leading cause of cancer in women accounting for more than 626,679 deaths only in 2018 [2]. In many cases this disease has become fatal because of its multifactorial origin and also because it has a great number of exogenous and endogenous factors that can stimulate different pathways [3]. In early BrC, gene expression profiles are determined for hormone receptor (HR)-positive disease and human epidermal growth factor type 2 receptor (HER2) status which define if a patient is likely to receive systemic therapy and are therefore used to guide their treatment [4]. Approximately 60–70% of primary BrC cases express positive estrogen receptors (ER+) or positive progesterone receptors (PR+) or both and are hormone responsive. However, about 15–20% of BrC cases are in the category of triple-negative phenotype owing to their lack of ER, PR, and amplified HER2. Commonly, ER+ hormone-dependent BrCs have a better prognosis and are often responsive to antihormone therapy [4].

Because of these reasons, the survival rates for BrC have decreased significantly; however, there have been great advancements in new alternative therapies which not only are safer but are also more effective and inexpensive and have minimal side effects [5]. Therapeutic drugs derived from natural compounds have become of great interest since more than 75% of anticancer drugs were designed and developed from plant-derived natural ingredients which have been proven to have anticancer properties with novel mechanisms [6]. In the last 50 years, nearly 200 new chemical compounds have been approved to fight cancer, of which around 50% are molecules of unmodified natural products and their semisynthetic or synthetic derivatives that are safe and profitable [7, 8]. Small organic molecules such as terpenes, flavonoids, alkaloids, lignans, saponins, vitamins, minerals, glycosides, oils, and other secondary metabolites play a significant role in either the inhibition of proliferation, induction of apoptosis, or other mechanisms that may be altered [9, 10]. The structural diversity of natural products and their wide application in therapeutics have always been recognized by pharmaceutical industries [1].

This chapter summarizes the small novel organic molecules obtained from plants and their derivatives, some of which are on the market and others are found in preclinical studies with encouraging results. We also describe some interesting biotechnological associations between some compounds and nanoparticles or other molecules as antibodies that show a novel potential in the treatment of BrC.


2. In vitro models for studying plant-derived compounds in breast cancer

The evaluation of the therapeutic potential of novel plant-derived compounds or secondary metabolites, either pure compounds or the mixture of active constituents, can serve as chemotherapeutic agents in BrC. The biological models used for the development of new drugs include in vitro models using BrC cell lines and are divided into estrogen receptor positive (ER+, T47, MCF-7) and ER negative (ER-, MDA-MB-231, MDA-MB-453, SKBR3). MDA-MB-231 or triple-negative breast cancer cell (TNBC) line, estrogen negative (ER-) and progesterone negative (PR-), and HER- are known to be models for metastasis, which are more aggressive, containing a high potential to metastasize, and are unresponsive to antiestrogens [5, 8]. TNBC line is used to investigate the mechanism underlying migration and invasion. It is important to find cancer therapeutic compounds which possess multi-targeted and multifunctional potential with anti-metastasis activity [8, 11]. MCF-7 is the most used cell line with a great number of publications due to the presence of ER+ [9].

In vitro experiments have also been used in different studies, in order to characterize and identify compounds derived from extracts, essential oils, and other extractions. Trypan blue dye, MTT, sulforhodamine B, and lactic dehydrogenase assays constitute some of the most utilized assays used to evaluate the cytotoxic effect of essential oils and/or pure compounds in different cell lines of BrC. In order to characterize morphological changes, biochemical and molecular levels of cell death, proteins that are modified (expression and activation), gene regulation, migration, invasion, and cell division, among other changes, experiments such as staining with hematoxylin and eosin, Western blot, TUNEL, annexin V, qRT-PCR, scratch assay, and cell cycle assays are performed [12].


3. In vivo models for studying plant-derived compounds in breast cancer

Wide varieties of animal model systems are now available to investigate plant-derived compounds in different stages, such as cancer initiation, promotion progression, invasion, and metastasis. These models are also used to comprehend therapeutic response, which represents an essential step between in vitro systems and clinical studies [8, 13]. The in vivo models are also used to investigate the capability of plant formulation to induce an anti-BrC effect where it is sought to optimize dose, bioavailability, administration routes, and selective delivery and reduce toxic effects, among others [8, 14]. The two animal species that will be mentioned in this review are those involving mice and rats [14]; however, BrC mouse models are used in a variety of preclinical studies [13].

There are different types of in vivo models of BrC, such as cell line-derived xenografts (MDA-MB-231 line) that are implanted into immunocompromised animals (cell-derived xenografts, CDX). CDX models represent a relatively homogenous mass of transformed breast epithelial cells, and depending on where the cells are inoculated, they are classified as ectopic CDX (models advanced disease only, subcutaneous injection of human tumor cells), orthotopic CDX (in mammary gland/fat pad), metastatic CDX (following tail vein or intra-cardiac injection in specific sites, i.e., bone or lung), syngeneic (mouse tissue implanted to strain-matched host) or metastasis with syngeneic model (usually fast-growing tumors and microenvironment derive from the same species, i.e., 4T1 cells), and genetically engineered mouse models (GEMMs) to address early events of tumorigenesis [13]. Nonetheless, researchers need to consider the limitations of each model and the mechanism of action of the compound previously investigated in in vitro models.


4. Cytotoxicity of plant-derived compounds

Plants produce bioactive secondary metabolites such as flavonoids [15], terpenoids [1], alkaloids [16], tannins, and others, which have profusely been studied for BrC (1, 8). Here, we describe some terpenoid compounds such as D-limonene, camptothecin (CPT), paclitaxel, and ursolic acid (UA) and some flavonoids such as cynaroside, isoflavones as Biochanin A (BA) or ginsenoside R2, naringenin, and other novel cytotoxic compounds from different natural sources as shown in Figure 1 and Table 1 .

Figure 1.

Molecular targets of plant-derived compounds in BrC.

SourceCompoundStudy typeConcentrationRef
Apples, herbs and spices including rosemaryUrsolic acid (UA)MCF-7, MDA-MB-231221.39 μg/ml 239.47 μg/ml[33]
Apiaceae family, Cuminum cyminumCynarosideMCF-7IC50:3.98 μg/ml[42]
Soybeans, soy foods, legumesBiochanin (BA)MCF-7, MDA-MB-23163.76 μm and 59.76 μm, respectively[44]
Soybeans, soy foods, legumesGinsenoside (Rh2)MCF-7, MDA-MB-23157.53 μm and 52.53 μm, respectively[44]
Soybeans, soy foods, legumesGinsenoside + biochaninMDA-MB-231
27.68, 25.41 μm; 25.2 μm, and 22.75 μm[44]
Tomatoes (Solanum lycopersicum), citrus fruits and grapesNaringeninMDA-MB-23140 μg/ml[43]
Soy productsGenistein (GEN)MCF-7,
100 μm[48]
Tomatoes (Solanum lycopersicum), other red fruitsLycopene (LYC)MDA-MB-231
≥1.25 μm to
5 μl in TNBC.
50 μm
[11, 12]
LYC incorporated biopolymeric nanoparticles with whey protein isolateLycopene (LYC-WPI-NPs)MCF-725–50 μm/ml[49]
A derivative from D-limonenePerillyl alcohol a hydroxylated product of D-limoneneKPL-1, MCF-7, MKL-F,
500 μm[26]
Taxus brevifoliaPaclitaxelMCF-7
100–500 nm[28]
Taxus brevifoliaPaclitaxel-loaded nanospheresMDA-MB-435, ZR.75.10.06–0.6 ng/ml[50]
Grapes, wine, nuts, berriesResveratrolMCF-710–150 μm[51]
Camptotheca accuminataCamptothecinMDA-MB-231
100 nm
IC50:0.65 nm
[52, 53]
Curcuma longaCurcuminMCF-7
IC50: 29 μg/ml
IC50: 35 μm
IC50: 30 μm
[54, 55]
Vinca alkaloidsVincristineMCF-7,
IC50: 170 and 50 nmol/L[56]

Table 1.

Cytotoxic effect of plant-derived compounds in in vitro models of BrC.

The anti-BrC activities of plant-derived compounds discussed in this chapter are taken from published articles that demonstrated an anti-BrC activity against specific cancer cell lines (see Table 2 ) and in vivo models (see Table 3 ) or clinical studies with their mechanism of action.

CompoundStudy typeDose and activityRef
D-LimoneneDMBA and NMU-induced mammary carcinogenesis in rats10% of limonene diet. Induced complete regression of primary rat mammary tumors and prevented the development of secondary tumors[24]
Perillyl alcohol a hydroxylated product of D-limoneneMammary rat tumor induced with KPL-1 cells75 mg/kg. Suppressed orthotopically transplanted KPL-1 tumor cell growth and regional lymph node metastasis in a nude mouse system[26]
Paclitaxel-encapsulated liposomesDMBA mammary tumor20 mg/kg. In combination with 500 mg/kg of Eruca sativaextract reduced NF-κB, COX-2 and Bcl-2 gene expression[97]
Paclitaxel-loaded nanospheresTumor xenograft model in mice5–50 mg/kg. Showed an equivalent antitumor efficacy to the clinical formulation and provided a superior safety and improved tolerability to higher paclitaxel doses[50]
ResveratrolDMBA induced mammary cancer in rats
estrogen-induced breast carcinoma in rats
100 μg/rat. Suppressed COX-2 and matrix metalloprotease-9 expression in the breast tumor.
50 mg. Inhibits breast carcinogenesis via induction of NRF2-mediated protective pathways
[67, 98]
CurcuminMCF-7 xenografts mouse breast cancer model100 mg/kg in combination with mitomycin 1–2 mg/kg. The combined treatment inhibited tumor growth, induced G1 arrest, and decreased cyclin D1, cyclin E, cyclin A, CDK2, and CDK4[99]
CamptothecinMouse 4T1 breast tumor model2 mg/kg in combination with 1.05 mg/kg of doxorubicin. Induced 70% of tumor volume reduction and caspase-3 induction[100]

Table 2.

Compounds evaluated in in vivo model of BrC.

Table 3.

Structures of plant-derived compounds with potential effect in the BrC treatment.

4.1 Terpenoids as cytotoxic compounds

Terpenoids are organic compounds derived from five-carbon units (isoprene) assembled and modified in different ways. The classification of terpenoids is based on the isoprene units which are commonly classified as monoterpenes (C10) and diterpenes (C20), i.e., paclitaxel, and triterpenes as ursolic acid [1]. Interestingly, essential oils are a rich and complex composition of monoterpenes with anti-BrC activity such as Decatropis bicoloressential oil (DBEO) [17].

4.1.1 D-limonene

D-limonene, (1-methyl-4-(1-methylethenyl-cyclohexene) a monocyclic monoterpene, with a molecular mass of 136.23 g/mol [18], is found in the peels of citrus fruits [18, 19, 20]. The main mechanism described by D-limonene is the inhibition of the posttranslational isoprenylation of cell growth-regulatory proteins such as Ras, inducing cell death. It has also demonstrated to decrease the viability of cancer cells in a dose-dependent manner by inducing apoptotic cell death. It induced the activation of caspase-3 and caspase-9, PARP cleavage, and Bax protein and cytosolic release of cytochrome c from the mitochondria and through the attenuation of the expression of Bcl-2 protein, suggesting that D-limonene induces apoptosis via the mitochondrial pathway and through the suppression of the PI3K/AKT pathway [21, 22]. The interest in this compound as a potential cancer chemotherapeutic agent was stimulated by pronounced chemopreventive and chemotherapeutic efficacy in spontaneous and carcinogen-induced animal tumor models with little toxicity [19, 22]. In the in vivo models, it has been reported to exhibit various effects on several hallmarks of cancer (i.e., proliferation, apoptosis, inflammation) [23, 24]. 7,12-Dimethylbenz(a)anthracene (DMBA) and N-methyl-N-nitrosourea (MNU) induced mammary carcinogenesis in rats and induced regression of carcinomas [24, 25, 26]. Dietary feeding of D-limonene also inhibited the development of Ras oncogene in mammary carcinomas in rats [25].

4.1.2 Paclitaxel

Paclitaxel is a complex diterpene, with a molecular structure of C47H51NO14 and a molecular mass of 853.91 g/mol [18]. This compound induces mitotic arrest and also apoptosis by activating extrinsic or intrinsic pathway. In MCF-7 cells it decreased levels of Bcl-2 protein and increased proapoptotic proteins such as Bax, cytochrome c, caspase-9, and caspase-3 [27, 28]. Likewise, it has also been reported that the induction of apoptosis was independent of caspases [29]. The combination of paclitaxel with a compound that inhibits the mitotic slippage such as phenylethyl isothiocyanate (PEITC) induced apoptosis in MDA-MB-231 cells which are drug resistance [30]. Also, additional activities of taxol have been described including the effect on cell signaling and gene expression and activation of mitogen-activated protein kinases (MAPKs), Raf-1, and protein tyrosine kinases [29]. Paclitaxel has been approved by the FDA to be used alone, or in combination with other anticancer treatments, to treat BrC and other cancers [31, 32].

4.1.3 Ursolic acid

Ursolic acid (3-β-hydroxy-urs-12-en-28-oic acid) is a pentacyclic triterpenoid natural product and a member of the cyclosqualenoid family, commonly named as UA with a molecular structure of C30H48C3 and a molecular mass of 456.7 g/mol [18]. UA is derived from diverse plants and fruits, such as rosemary (Rosmarinus officinalis), apple (Malus domestica), makino, cranberries (Vaccinium macrocarpon), pears (Pyrus pyrifolia), prunes (Prunus domestica), bearberries (Arctostaphylos alpina), loquat (Eriobotrya japonica), scotch heather (Calluna vulgaris), basil (Ocimum sanctum), and jamun (Eugenia jambolana) [9, 11]. UA posed different activity against BrC via several molecular mechanisms [7, 11, 33, 34, 35], and UA is relatively nontoxic to normal cells [11]. Administration of UA demonstrates inhibitory efficacy against cell proliferation rate and induces apoptosis via both the mitochondrial death pathway (cleavage of caspase-9, caspase-3, and PARP, Bax upregulation and Bcl-2 downregulation, release of cytochrome c to the cytosol, decreased mitochondrial membrane potential) and extrinsic death receptor-dependent pathway (Fas receptor) in MDA-MB-231 cells [9, 11]. The treatment of BrC cells with UA induced changes in glycolytic pathway leading to cytotoxic autophagy, also at low doses (5–20 μm) caused a G0/G1 cell cycle arrest, increased p21 levels, oxidative stress, and DNA damage [36]. UA has been demonstrated to exhibit strong anti-BrC potential by inducing cell cycle arrest and inhibition of proliferation, angiogenesis, and metastasis in both in vitro and in vivo models [7, 11, 33, 34, 35]. Finally, UA inhibited BrC growth by inducing cell death via the inhibition of inflammatory responses through the NF-κB, PI3K/AKT signaling pathways [9, 33]. Therefore, UA could be used as a potential anti-BrC strategy in clinical studies.

4.1.4 Lycopene alone

Lycopene (LYC) (trans-lycopene) is a terpene assembled from eight isoprene units and is a rich antioxidant compound, a major carotenoid present in tomatoes (Solanum lycopersicum), apricots, red oranges, pink grapefruit, watermelon, rose hips, guava, vegetables, and photosynthetic algae [37]. LYC has a molecular structure of C40H56 and a molecular mass of 536.888 g/mol [18]. LYC is a compound that has displayed antiproliferative, anti-migration, anti-invasive, anti-metastatic, and antioxidant characteristics in numerous in vitro and in vivo studies in BrC [9, 37, 38, 39]. Also, LYC induces apoptosis and activates caspase-9 enzyme in human BrC cells [9]. Finally, LYC has inhibited the multiplication of cancer cells by arresting cell cycle at different phases (G1, S, and M phases) and by sustained activation of the ERK½ with suppression of cyclin D1 and upregulation of p21 [39]. Other mechanism of action of LYC is through the inhibition of IκBα phosphorylation and decrease in the expression of NF-κB [40].

4.1.5 Decatropis bicoloressential oil: a mixture of monoterpenes

Essential oils are a complex mixture of secondary metabolites such as monoterpenes that are responsible for their biological activity that includes anti-BrC effect. However, some studies suggested a synergistic activity of the compounds [17]. For example, DBEO was studied on MDA-MB-231 cells.

It had a cytotoxic effect with an IC50 of 53.81 μg/ml. It induced DNA fragmentation and apoptosis via intrinsic pathways due to the activation of Bax, caspase-9, and caspases-3, suggesting a synergistic activity of compounds present in the essential oil, such as 1,5-cyclooctadiene, 3-(methyl-2)propenyl, β-terpineol, 1-(3-methyl-cyclopent-2-enyl)-cyclohexene, D-limonene, pinene, and linalool [41].

4.2 Flavonoids as cytotoxic compounds

Flavonoids which are polyphenolic substances found in different plant-derived food are divided into flavones (cynaroside), flavonols, flavanones (naringenin), flavanols, isoflavones (genistein (GEN), biochanin A), anthocyanidins, and nonflavonoids [10]. Flavonoids have been reported to have an effect on BrC through numerous mechanisms such as antioxidant, anti-inflammatory, antiproliferative, cytotoxic, anti-angiogenic, and anti-metastatic effects in numerous in vitro and in vivo experiments in estrogen-dependent or estrogen-independent BrC [15, 37] ( Tables 1 3 ).

4.2.1 Cynaroside

Cynaroside (luteolin-7-O-glucoside) is a glycosyloxyflavone or a glycoside form. It derives from luteolin. Cynaroside has a molecular structure of C21H20O11 and a molecular mass of 448.38 g/mol [18]. Cynaroside is a constituent of the leaves of Capsicum annuum(red pepper) and seeds and fruits of Cuminum cyminum, an old famous medicinal and culinary plant from the Apiaceae family. Currently, Goodarzi and collaborators demonstrated that luteolin-7-O-glucoside plays a significant role in cytotoxic effect of C. cyminumagainst MCF-7 cell line (IC50 of 3.98 μg/ml) and can be introduced as a candidate for chemopreventive and chemotherapeutic drugs [42]. More in vitro or in vivo studies are necessary to elucidate its mechanism of action.

4.2.2 Naringenin

Naringenin (4',5,7-trihydroxyflavanone) is a flavanone and member of 4'hydroxyflavanones; it has a molecular structure of C15H12O5 and a molecular mass of 272.256 g/mol [18]. This bioflavonoid is a constituent of tomatoes, citrus fruits, and grapes. Naringenin is a phytoestrogen which is also an important anti-BrC, reported to be involved in decreasing the number of ER-α-positive cells by modulating p38 MAPK signaling pathway [9]. Recently, investigators reported that naringenin has antiproliferative effects by arresting the cell cycle at the G2 phase and caused an inhibitory effect on MDA-MB-231 cells via induction of apoptosis and inhibition of caspase-3 and caspase-9 activities [37, 43].

4.2.3 Biochanin and ginsenoside Rh2 as pure compounds or mixture

Biochanin or 4'-methylgenistein (B5,7-dihydroxy-4’-methoxyisoflavone) is an O-methylated isoflavone that is isolated from red clover Trifolium pratenseand the root of Astragalus membranaceus, a traditional Chinese herbal medicine. BA has a molecular structure of C16H12O5 and a molecular mass of 284.267 g/mol [18, 44]. The phytoestrogen BA caused antiproliferative activity by stabilizing and activating p53 through the upregulated expression of phospho-p53, phospho-p38, and p-ASK1 and downregulated expression of TRAF2 in MDA-MB-231 and MCF-7 cells [44] and apoptosis through upregulated expression of mRNA levels of ER-α, Bcl-2, and miR-375 in ER+ BrC cells, that is to say T47D and MCF-7 [37, 44, 45].

Also, BA stopped cell growth by blocking the activity of aromatase enzyme which is encoded by the gene CYP19 [5]. On the other hand, ginsenoside Rh2 (protopanaxadiol-type) is the major type of saponin ginsenoside that is separated from Panax ginsengand other species. Rh2 has a molecular structure of C36H62O8 and a molecular mass of 622.884 g/mol [18, 44]. Rh2 exhibits antitumor activity in ER+(MCF-7) and ER-(MDA-MB-231). However, Ren and collaborators determined that BA plus Rh2 synergistically enhanced the antiproliferative effect in both BrC cells, with decreased EC50 values of both the compounds and a mechanism through the stabilization and activation of p53, p38, and ASK1 proteins ( Table 1 ) [44].

4.2.4 Genistein

Genistein (4',5,7-trihydroxyisoflavone) is an isoflavonoid derived from soy products [46]. It has a molecular structure of C15H10O5 and a molecular mass of 270.24 g/mol [18]. This agent has an antineoplastic effect in BrC [47]. GEN inhibits the growth of MDA-MB-231 cells by altering the phosphorylation of proteins included in cell cycle regulation and DNA damage response predominantly, and GEN induced apoptosis via the upregulation of Bax and p21WAF1 proteins in MDA-MB-231 cells and downregulating the expression of caspase-3 [5, 47]. In a recent study, GEN increases cell cycle arrest in G2/M phase in MDA-MB-231/ERβ1 cells, even though there is a high dose of GEN-arrested cells in G0/G1, just like in the MCF-7 cells. Thus, the combinatorial effect of GEN and overexpressed ERβ1 resulted in an active blockade of cell cycle progression and a dramatic inhibition of proliferation in vitro in MCF7 and MDA-MB-231 cells [48]. GEN could be a potential therapeutic agent for ERβ1-positive cancer, which merits further clinical research in the future.

4.2.5 Resveratrol

Resveratrol (3,5,4′-trihydroxy-trans-stilbene) is a natural nonflavonoid polyphenol with a molecular formula of C14H12O3 [18]. These compounds are isolated from more than 72 species of plants including peanuts, grapes, mulberries, bilberries, and blueberries [9].

Numerous in vitro studies have shown that resveratrol has multiple anticancer effects, which protect the cells against both tumor initiation and cancer progression pathway [9, 57]. The activity of this compound was described in hormone-dependent or non-hormone-dependent BrC cells, in which it was found to induce apoptosis by intrinsic pathway through the upregulation of Bax, Bak, caspase-3, p53, and Akt pathway in different breast cancer cell lines and downregulated Bcl-2 and NF-kB and VEGF [51, 58, 59, 60, 61, 62]. Also, it can induce the extrinsic pathway through the expression of CD95 receptor [63]. A cell surface resveratrol receptor on the extracellular domain of heterodimeric αVβ3-integrin in MCF-7 human BrC cells induces extracellular-regulated kinases 1 and 2 (ERK1/2) and serine-15-p53-dependent phosphorylation leading to a p53-dependent apoptosis [57]. In several in vivo models, resveratrol supplementation was shown to decrease the incidence of mammary tumor formation, tumor volume, metastasis, and induced apoptosis [64, 65, 66]. The effect of resveratrol demonstrated lower tumor growth, decreased angiogenesis, and increased apoptotic index in ERα− and ERβ+ [62]. Also, the following can suppress mammary carcinogenesis in rats induced by DMBA: dietary administration of resveratrol (10 ppm), downregulation of NF-kB, cyclooxygenase-2 and matrix metalloprotease-9 expression in the breast tumor, and decreased tumor incidence [67, 68].

The effect of resveratrol in cancer patients has been investigated in a few clinical trials. The first clinical trial dealing with resveratrol and cancer was performed by Nguyen and collaborators in 2009, through the administration of 0.07 mg/day of resveratrol which resulted in the reduction of Wnt target gene expression, indicating that it may play a beneficial role in the prevention of cancer. These clinical trials have demonstrated resveratrol to be a promising therapeutic and chemopreventive agent [64, 69, 70].

4.2.6 Curcumin

Curcumin (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) is an orange-yellow component of turmeric or curry powder; it is a polyphenol natural product isolated from the rhizome of Curcuma longa[9, 71]. Curcumin has antiproliferative and proapoptotic effects against a variety of cancer cells in vitro. The anticancer effects observed by activating intrinsic apoptotic pathway by interacting with reactive oxygen species can release cytochrome C; upregulate caspase-9, caspase-3, Bax, and Bad; downregulate Bcl-2 antiapoptotic proteins; and induce DNA fragmentation in different BrC cell lines [72, 73, 74, 75]. Also, it was found that curcumin inhibits the expression of Ki-67, proliferating cell nuclear antigen (PCNA), p53, and VEGF in BrC cells [54, 76]. Curcumin prevents carcinogen-induced cancers in rodents [77]. Banerjee et al. [79] reported that curcumin-induced G2/M arrest and apoptosis inhibited cell proliferation in MCF-7 cells, leading to an accumulation in the G1 phase, and suppressed the expression of zeste homolog 2 (EZH2) gene via MAPK pathway [78, 79].

4.3 Alkaloids as cytotoxic compounds

Alkaloids are a highly diverse group of compounds containing an organic nitrogen atom and a ring structure. Additionally, in most alkaloids the nitrogen atom is located inside the heterocyclic ring structure, which gives them a great biological diversity [16]. The structural diversity of this family is due to the wide number of amino acids used as building blocks [80]. Indeed, the peptide ring that they contain has one or more of its hydrogen atoms replaced with various alkyl radicals, most of which contain oxygen [81, 82]. Consequently, alkaloids can interact with a wide spectrum of molecules. They have a wide distribution in the plant kingdom and are a chemically heterogeneous group of ~17,000 molecules which have displayed pronounced biological and pharmacological activities. Furthermore, several alkaloids exhibit significant biological activities, with their unlimited supply of variable structures as well as their relatively low toxicity and well-documented stability; therefore, alkaloids are being used for their anticancer activity against various cancers [83].

4.3.1 Camptothecin

Camptothecin is a monoterpene indole alkaloid that consists of five rings [18], commonly named as CPT with a molecular structure of C20H16N2C4 and a molecular mass of 348.35 g/mol [18]. The antitumor activity of this compound is mainly due to its interaction with topoisomerase I (Top1), an enzyme involved in the regulation of DNA topology during replication, recombination, and transcription. It induces cell death by stabilizing a covalent complex between DNA topoisomerase I and the nicked DNA, leading to a DNA lesion [84, 85, 86, 87].

CPT antitumoral activity has been reported in different cancer cell lines. Low doses of this compound lead to cell cycle arrest in the G2/M phase and inhibit DNA synthesis but at higher doses cause cell cycle arrest in S phase [52]. Also, the expression of some genes as c-Myc, Bax, BFL1, Bak, pRb2, c-Jun, and Jun-B was upregulated, and Cdk4, cyclin B1, Wee1, CRAF1, and DP1 were downregulated. Among these derivatives, camptothecin-20(s)-O-(2-pyrazolyl-1)acetic ester exhibited antitumor activity which demonstrated cytotoxicity, DNA fragmentation, and apoptosis toward MCF-7 cell line [53]. Also, in different studies in vivo, where it was delivered using an intralipid formulation through intramuscular (IM) route, CPT showed nearly 100% growth inhibition and regression in the colon, lung, breast, stomach, and ovary and malignant melanoma xenografts [88, 89].

4.3.2 Vinca alkaloids: vinblastine, vincristine, and vinorelbine

There are some vinca alkaloids in clinical use such as vinblastine, vinorelbine, and vincristine. Many alkaloids have poisonous characteristics but also have physiological effects that make them useful as medications. The oldest group of the plant alkaloids used to treat cancer is the vinca alkaloids. They have a dimeric chemical structure composed of two basic multi-ringed units, an indole nucleus (catharanthine) and a dihydroindole nucleus (vindoline), joined together with other complex systems. Structurally, vincristine and vinblastine are identical except for a single substitution on the vindoline nucleus, where vincristine and vinblastine possess formyl and methyl groups, respectively [90, 91] ( Table 2 ). The main mechanisms of vinca alkaloid cytotoxicity is due to their interactions with tubulin and disruption of microtubule function, particularly of microtubules comprising the mitotic spindle apparatus, directly causing metaphase arrest. The disturbing effects occur at drug concentrations below those that decrease microtubule mass [91, 92]. Also, disorganization of the microtubule structure provokes the induction of tumor suppressor gene p53 and activation/inactivation of several protein kinases involved in key signaling pathways, including p21, WAF1/CIP1, Ras/Raf, and PKC/PKA, the apoptosis inhibitor Bcl2 and induction of Bax triggering the process of apoptosis in the cell [93]. These alkaloids demonstrated significant antitumor activity in patients with BrC. Also, xenograft mice models were used to evaluate low doses of vinblastine, which resulted in significant but transient xenograft regression, diminishing tumor vascularity, and direct inhibition of angiogenesis. Also, a combination therapy resulted in full and sustained regressions of large established tumors, without an ensuing increase in host toxicity or any signs of acquired drug resistance during treatment [94].

The risk of side effects and multidrug resistance limited the development of vinca alkaloids for clinical applications. To solve these problems, researchers have developed numerous strategies, such as using liposome-entrapped drugs, chemically modified drugs, and polymeric packaging drugs, to reduce the toxicity and enhance the therapeutic efficiency of vinca alkaloids. Many liposome products are still being tested in clinical trials. Another strategy for reducing chemotherapeutic toxicity involves using chemically modified drugs [95, 96].


5. Biotechnological and clinical advances of plant-derived compounds in breast cancer

Nanotechnology has been found to potentially improve current methods for disease, diagnosis, disease-state imaging, and treatment in BrC.

Targeted nanoparticle drug delivery is intended to reduce the side effects of anticancer drugs with both decreasing consumption and treatment expenses, which are the major hurdles in conventional cancer treatment. These small entities can be used in combination with a variety of plant-derived compounds in BrC with a variety of formulations being developed, making them a desirable choice of drug formulation [8].

5.1 Use of phytochemical compounds coupled to nanoparticles

5.1.1 Lycopene with nanoparticles

Recently, Jain and collaborators designed and synthesized LYC incorporated with biopolymeric nanoparticles with whey protein isolate nanoparticles (WPI NPs) with encouraging results in the compatibility of LYC-WPI-NPs over plain LYC as an optimum delivery system in vitro because encapsulation process did not affect its anticancer activity even in in vivo tumor model of DMBA where ~57% of LYC group of animals developed tumor compared with ~29% of LYC-WPI-NPs. The new formulation (LYC-WPI-NPs) posed higher cytotoxicity and cellular uptake efficacy as compared to the plain LYC in MCF-7 cells. Antitumoral effect of LYC-WPI-NPs and survival data indicate that proposed formulation strategy is a novel approach for the synchronized delivery of bioactive compound, leading to increased bioavailability, therapeutic efficacy, and safety profiling because of improvement in animal survival (100%), in contrast to animals free of LYC (66.67%) and negative control group (16.67%). This will certainly open new avenues to explore cancer treatment [49].

5.1.2 Paclitaxel with nanoparticles

As a strongly hydrophobic drug, it requires suitable delivery vehicles to effectively distribute into tumor tissues. For efficient distribution of this hydrophobic anticancer drug, paclitaxel is currently formulated and administered to patients via polyethoxylated castor oil (Cremophor EL, CrEL), but it is reported as causing hypersensitivity reactions and neurotoxicity [101]. To date, paclitaxel albumin-bound nanoparticles (Abraxane®) have been approved by the FDA for the treatment of metastatic BrC and non-small cell lung cancer [8]. Nanoparticle-based delivery systems can take advantage of the enhanced permeability and retention (EPR) effect for passive tumor targeting; therefore, they can improve the therapeutic index and decrease the side effects of paclitaxel. In addition, there are a number of novel paclitaxel nanoparticle formulations in clinical trials [50, 101, 102, 103, 104]. Nanoparticle-assisted chemotherapeutic drug delivery has been used because it enhances therapeutic effectiveness. Studies on metastatic BrC demonstrate the inhibition of metastasis by co-delivering chemotherapeutic agent paclitaxel and twist shRNA via complex nanoparticles [105].

5.1.3 Camptothecin with nanoparticles

Research have concentrated on the development of potential delivery system to increase the aqueous solubility, stability, and bioavailability as well as controlled delivery of camptothecin at or around cancer tissues. For that purpose nanoencapsulation of drugs in a biodegradable polymer has been reported to protect the drug in the core of the polymeric shell [106, 107, 108]. Camptothecin encapsulated in nanoparticles demonstrated antitumor activity in in vitro and in vivo models; in MCF-7 cells the IC50 was lower (0.23 μm) than the pure compound (0.57 μm) [106, 109].

5.1.4 Curcumin with nanoparticles

As other compounds, in order to increase photostability and enhance its anticancer activity against BrC cells, scientists have formulated the transferrin-mediated solid lipid nanoparticle, which enhances the anticancer effect of curcumin in BrC cells in vitro [110]. A polymer-drug conjugate called polycurcumins also has advantages of high drug-loading efficiency, fixed drug-loading contents, stabilized curcumin in their backbones, and tailored water solubility. The polycurcumins are cytotoxic to cancer cells, but a polyacetal-based polycurcumin is highly cytotoxic to MCF-7 cells. The effect of these polymers induced cell cycle arrest and apoptosis partially through the caspase-3-dependent pathway. In vivo, this polymer showed antitumor activity in SKOV-3 intraperitoneal xenograft tumor model [111].

5.2 Novel therapies: antibody-phytopharmaceutical conjugates in breast cancer

In recent years, natural products and their derivatives have been among the major sources of drugs for the treatment of cancer as well as nanoparticles or antibodies. Furthermore, new treatments for different cases of BrC are necessary; this involves linking each cytotoxic drug concerned with a mAb by a linker group to produce a tripartite drug called an “antibody-drug conjugate” (ADC). A means of selective delivery of highly cytotoxic natural products as “prodrugs” to tumor cells has proven necessary in order to reduce off-target effects and increase therapeutic outcomes [8, 112].

5.2.1 Plant natural products as components of development ADCs: nab-paclitaxel or Abraxane®

The plant-derived compounds are secondary metabolites that have a different mechanism of action; although all of them are cytotoxic for BrC cells, new tools are being sought to increase their effectiveness, with less toxic effects. Also, incorporation of paclitaxel in liposomes can facilitate its delivery to cancer cells and eliminate the adverse reactions associated with the Cremophor EL vehicle. The lipid components of the liposomal formulation were nontoxic, but the intracellular paclitaxel levels were higher when MCF-7 cells were treated with the liposomal paclitaxel formulation; also, liposomal paclitaxel was as effective as conventional paclitaxel in inducing G2/M arrest after 1 day of treatment with 10 mmol/L, increasing the percentage of cells in this population from about 20% in cycling cells to over 60% after 7 days [104].

Abraxane® or nanoparticle albumin-bound paclitaxel (nab-paclitaxel) suspension demonstrated greater efficacy with less toxicity than docetaxel in metastatic BrC. This treatment has been approved to reduce toxicity and increased overall survival rates, compared to the parent compound [8]. Nab-paclitaxel is a neoadjuvant chemotherapy in HER2-negative BrC stages I, II, and III.

The recommended dose of Abraxane® is 260 mg/m2 administered intravenously for 30 minutes, every 3 weeks. The results suggest that Abraxane® is effective in patients with highly proliferative cancers (81).


6. Conclusion

In nature, plants contain secondary metabolites, which have been used by humans to treat different diseases, since they have a complex diversity of chemical structures that have been specifically related to have anti-BrC activity in several preclinical studies with more than one mechanism of action; as a result, they can provide greater degree of efficacy. Several natural compounds are highlighted in this chapter, and their mechanism of action, synergistic action, nano-formulations, and future potentials are widely discussed, and due to the promising potential they represent, in fact, some of them are already used as treatment for BrC. However, it is necessary to have a greater diversity of drugs to be able to treat each one of the different tumors of BrC, since each BrC is different and many of these drugs may still induce several side effects and the development of mechanisms of resistance to drugs must be avoided. Subsequent from this review, we can conclude that although there are many compounds that have been characterized mainly in in vitro models and only around 10–20% of these were also evaluated in in vivo models and less than 10% are being evaluated already in clinical phases, it is essential to conduct more research on these compounds to learn their mechanism of action. Also, in their cellular, biochemical, and molecular levels, clinical effects as well as their genetic toxicities should be investigated sufficiently. Compounds that meet the eligibility criteria in these tests should be taken into clinical trial phase, and they may be administered in combination with other compounds or materials that make their pharmacological effect more efficient, make their arrival to the target site more selective, and guarantee their stability, bioavailability, pharmacokinetics, etc. In conclusion, addressing the study of these compounds in clinical phase is a pressing need.



This work was supported by the Secretaría de Investigación y Posgrado del Instituto Politécnico Nacional Grants SIP20170567 and SIP20196913. CRC is supported by CONACyT and BEIFI, IPN Fellowships.


Conflict of interest

The authors declare that they have no competing interests.


  1. 1. Prakash V. Terpenoids as cytotoxic compounds: A perspective. Pharmacognosy Reviews. 2018;12:166-176. Available from:
  2. 2. Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2018;68(6):394-424. DOI: 10.3322/caac.21492
  3. 3. Pavlova NN, Thompson Craig B. The emerging hallmarks of cancer metabolism. Cell Metabolism. 2016;23(1):27-47. DOI: 10.1016/j.cmet.2015.12.006
  4. 4. Murphy C, Muscat A, Ashley D, Mukaro V, West L, Liao Y, et al. Tailored NEO adjuvant epirubicin, cyclophosphamide and nanoparticle albumin-bound paclitaxel for breast cancer: The phase II NEONAB trial—Clinical outcomes and molecular determinants of response. Plos One. 2019;14(2):1-20. DOI: 10.1371/journal.pone.0210891
  5. 5. Mitra S, Dash R. Natural products for the management and prevention of breast cancer. Evidence-Based Complementary and Alternative Medicine. 2018;2018:1-24. DOI: 10.1155/2018/8324696
  6. 6. Newman DJ, Cragg GM. Natural products as sources of new drugs from 1981 to 2014. Journal of Natural Products. 2016;79:629-661. DOI: 10.1021/acs.jnatprod.5b01055
  7. 7. Iqbal J, Ahsan B, Ahmad R, Mahmood T, Kanwal S, Ali B, et al. Ursolic acid a promising candidate in the therapeutics of breast cancer: Current status and future implications. Biomedicine & Pharmacotherapy. 2018;108:752-756. DOI: 10.1016/j.biopha.2018.09.096
  8. 8. Agarwal G, Carcache PB, Addo EM, Kinghorn AD. Current status and contemporary approaches to the discovery of antitumor agents from higher plants. Biotechnology Advances. 2019. DOI: 10.1016/j.biotechadv.2019.01.004
  9. 9. Iqbal J, Ahsan B, Mahmood T, Ali B, Talha A, Kanwal S, et al. Potential phytocompounds for developing breast cancer therapeutics: Nature’s healing touch. European Journal of Pharmacology. 2018;827:125-148. DOI: 10.1016/j.ejphar.2018.03.007
  10. 10. Avtanski D, Poretsky L. Phyto-polyphenols as potential inhibitors of breast cancer metastasis. Molecular Medicine. 2018;24(1). DOI: 10.1186/s10020-018-0032-7
  11. 11. Kim KH, Seo HS, Choi HS, Choi I, Shin YC, Ko S. Induction of apoptotic cell death by ursolic acid through mitochondrial death pathway and extrinsic death receptor pathway in MDA-MB-231 cells. Archives of Pharmacal Research. 2011;34(8):1363-1372. DOI: 10.1007/s12272-011-0817-5
  12. 12. Tariq A, Sadia S, Pan K, Ullah I, Mussarat S, Sun F, et al. A systematic review on ethnomedicines of anti-cancer plants. Physical Therapy Research. 2017;31(2):202-264. DOI: 10.1002/ptr.5751
  13. 13. Holen I, Speirs V, Morrissey B, Blyth K.In vivomodels in breast cancer research: Progress, challenges and future directions. Disease Models & Mechanisms. 2017;10:359-371. DOI: 10.1242/dmm.028274
  14. 14. Cekanova M. Animal models and therapeutic molecular targets of cancer: Utility and limitations. Drug Design, Development and Therapy. 2014;8:1911-1922
  15. 15. Sak K. Epidemiological evidences on dietary flavonoids and breast cancer risk: A narrative review. Asian Pacific Journal of Cancer Prevention. 2017;18(9):2309-2328
  16. 16. Lu J-J, Bao J-L, Chen X-P, Huang M, Wang Y-T. Alkaloids isolated from natural herbs as the anticancer agents. Evidence-based Complementary and Alternative Medicine. 2012;2012:1-12. DOI: 10.1155/2012/485042
  17. 17. Estanislao Gómez CC. PID and GGM. Biological activities of some essential oils from plants of Mexico. Journal of Complementary Medicine & Alternative Healthcare. 2017;3(3):3-6
  18. 18. U.S. National Library of Medicine. Pub Chem Identifier [Internet]. 2019. Available from:
  19. 19. Erasto P, Viljoen A. Limonene—A review: Biosynthetic, ecological and pharmacological relevance. Natural Product Communications. 2008;3(7):1193-1199
  20. 20. Malko MW, Wróblewska A, Chemical O. The importance of R-(+)-limonene as the raw material for organic syntheses and for organic industry. Chemik. 2016;70(4):193-202
  21. 21. Jia S, Xi G, Zhang M, Chen Y, Lei BO, Dong X, et al. Induction of apoptosis byD-limonene is mediated by inactivation of Akt in LS174T human colon cancer cells. Oncology Reports. 2013;3(23):349-354
  22. 22. Yang C, Chen H, Chen H, Zhong B, Luo X, Chun J. Antioxidant and anticancer activities of essential oil from gannan navel orange peel. Molecules. 2017;22(8):1-10. DOI: 10.3310.3390/molecules22081391
  23. 23. Miller JA, Pappan K, Thompson PA, Want EJ, Siskos AP, Keun HC, et al. Plasma metabolomic pro files of breast cancer patients after short-term limonene intervention. Cancer Prevention Research (Philadelphia, Pa.). 2015;8(1):86-93. DOI: 10.1158/1940-6207
  24. 24. Haag JD, Lindstrom MJ, Gould MN, Haag JD, Lindstrom MJ, Gould MN. Limonene-induced regression of mammary carcinomas limonene-induced regression of mammary carcinomas. Cancer Research. 1992;52(14):4021-4026
  25. 25. Gould N, Moore J, Kennan S, Haag JD. Limonene chemoprevention of mammary carcinoma induction following direct in situ transfer of v-ha-ras1. Cancer Research. 1994;54(13):3540-3543
  26. 26. Yuri T, Danbara N, Tsujita-kyutoku M, Kiyozuka Y, Shikata N, Kanzaki H, et al. Perillyl alcohol inhibits human breast cancer cell growthin vitroandin vivo. Breast Cancer Research and Treatment. 2004;84(3):251-260
  27. 27. Thomadaki H, Talieri M, Scorilas A. Treatment of MCF-7 cells with taxol and etoposide induces distinct alterations in the expression of apoptosis-related genes BCL2, BCL2L12, BAX, CASPASE-9 and FAS. Biological Chemistry. 2006;387(8):1081-1086. DOI: 10.1515/BC.2006.133
  28. 28. Tudor G, Aguilera A, Halverson DO, Laing ND. Susceptibility to drug-induced apoptosis correlates with differential modulation of Bad, Bcl-2 and Bcl-x L protein levels. Cell Death and Differentiation. 2000;7(6):574-586. DOI: 10.1038/sj.cdd.4400688
  29. 29. Ofir R, Seidman R, Rabinski T, Krup M, Yavelsky V, Weinstein Y, et al. Taxol-induced apoptosis in human SKOV3 ovarian and MCF7 breast carcinoma cells is caspase-3 and caspase-9 independent. Cell Death and Differentiation. 2002;9:636-642
  30. 30. Flores ML, Castilla C, Ávila R, Ruiz-Borrego M, Sáez C, Japón MA. Paclitaxel sensitivity of breast cancer cells requires efficient mitotic arrest and disruption of Bcl-xL/Bak interaction. Breast Cancer Research and Treatment. 2012;133(3):917-928. DOI: 10.1007/s10549-011-1864-9
  31. 31. Barbuti AM, Chen Z. Paclitaxel through the ages of anticancer therapy: Exploring its role in chemoresistance and radiation therapy. Cancers (Basel). 2015;7(4):2360-2371. DOI: 10.3390/cancers7040897
  32. 32. Weaver B. How taxol/paclitaxel kills cancer cells. Molecular Biology of the Cell. 2014;25(18):2677-2681. DOI: 10.1091/mbc.E14-04-0916
  33. 33. Luo J, Hu YANL, Wang H. Ursolic acid inhibits breast cancer growth by inhibiting proliferation, inducing autophagy and apoptosis, and suppressing inflammatory responses via the PI3K/AKT and NF-κ B signaling pathwaysin vitro. Experimental and Therapeutic Medicine. 2017;14:3623-3631. DOI: 10.3892/etm.2017.4965
  34. 34. Pironi AM, Araújo PR De, Fernandes MA. Nunes Salgado RA and Chorilli M. Characteristics, biological properties and analytical methods of ursolic acid: A review. Critical Reviews in Analytical Chemistry. 2017:1-25. DOI:10.1080/10408347.2017.1390425
  35. 35. Hasanpourghadi M, Kumar A, Rais M. Modulation of oncogenic transcription factors by bioactive natural products in breast cancer. Pharmacological Research. 2018;128, 128:376-388. DOI: 10.1016/j.phrs.2017.09.009
  36. 36. Lewinska A, Adamczyk J, Ewa G. Ursolic acid-mediated changes in glycolytic pathway promote cytotoxic autophagy and apoptosis in phenotypically different breast cancer cells. Apoptosis. 2017. DOI: 10.1007/s10495-017-1353-7
  37. 37. Subramani R, Lakshmanaswamy R. Complementary and alternative medicine and breast cancer. Progress in Molecular Biology and Translational Science. 2017:1-44. DOI: 10.1016/bs.pmbts.2017.07.008
  38. 38. Surh Y-J. Cancer chemoprevention with dietary phytochemicals. Nature Reviews. 2003;3:768-780. DOI: 10.1038/nrc1189
  39. 39. Forcados GE, James DB, Sallau AB, Muhammad A, Mabeta P. Oxidative stress and carcinogenesis: Potential of phytochemicals in breast cancer therapy. Nutrition and Cancer. 2017:1-10. DOI: 10.1080/01635581.2017.1267777
  40. 40. Assar EA, Vidalle MC, Chopra M, Hafizi S. Lycopene acts through inhibition of IκB kinase to suppress NF-κ B signaling in human prostate and breast cancer cells. Tumor Biology. 2016;37(7):9375-9385. DOI: 10.1007/s13277-016-4798-3
  41. 41. Estanislao Gómez CC, Aquino Carreño A, Pérez Ishiwara DG, San Martín Martínez E, Morales López J, Pérez Hernández N, et al. Decatropis bicolor (Zucc) radlk essential oil induces apoptosis of the MDA-MB-231 breast cancer cell line. BMC Complementary and Alternative Medicine. 2016;16(1):266-276. DOI: 10.1186/s12906-016-1136-7
  42. 42. Goodarzi S, Tabatabaei MJ, Jafari RM, Shemirani F, Tavakoli S, Mofasseri M, et al. Cuminum cyminum fruits as source of luteolin-7-O-glucoside, potent cytotoxic flavonoid against breast cancer cell lines. Natural Product Research. 2018:1-5. DOI: 10.1080/14786419.2018.1519824
  43. 43. Wang RUI, Wang J, Dong T, Shen JUN, Gao X, Zhou JUN. Naringenin has a chemoprotective effect in MDA-MB-231 breast cancer cells via inhibition of caspase-3 and -9 activities. Oncology Letters. 2019;17:1217-1222. DOI: 10.3892/ol.2018.9704
  44. 44. Ren G, Shi Z, Cong T, Yao Y. Antiproliferative activity of combined Biochanin A and Ginsenoside Rh2 on MDA-MB-231 and MCF-7 human breast cancer cells. Molecules. 2018;23(2908):1-14. DOI: 10.3390/molecules23112908
  45. 45. Chen J, Ge B, Wang Y, Ye Y, Zeng S, Huang Z. Biochanin a promotes proliferation that involves a feedback loop of MicroRNA-375 and estrogen receptor alpha in breast cancer cells. Cellular Physiology and Biochemistry. 2015;35:639-646. DOI: 10.1159/000369725
  46. 46. Pfeffer CM, Singh ATK. Apoptosis: A target for anticancer therapy. International Journal of Molecular Sciences. 2018;19:1-10. DOI: 10.3390/ijms19020448 2018;2
  47. 47. Fang Y, Zhang Q , Wang X, Yang X, Wang X, Huang Z, et al. Quantitative phosphoproteomics reveals genistein as a modulator of cell cycle and DNA damage response pathways in triple-negative breast cancer cells. International Journal of Oncology. 2016;48:1016-1028. DOI: 10.3892/ijo.2016.3327
  48. 48. Jiang H, Fan J, Cheng L. The anticancer activity of genistein is increased in estrogen receptor beta 1-positive breast cancer cells. OncoTargets and Therapy. 2018;11:8153-8163
  49. 49. Jain A, Sharma G, Ghoshal G, Kesharwani P, Singh B, Shivhare US, et al. Lycopene loaded whey protein isolate nanoparticles: An innovative endeavor for enhanced bioavailability of lycopene and anti-cancer activity. International Journal of Pharmaceutics. 2018;30(546):97-105. DOI: 10.1016/j.ijpharm
  50. 50. Sheihet L, Garbuzenko OB, Bushman J, Gounder MK, Minko T, Kohn J. European journal of pharmaceutical sciences paclitaxel in tyrosine-derived nanospheres as a potential anti-cancer agent:In vivoevaluation of toxicity and efficacy in comparison with paclitaxel in cremophor. European Journal of Pharmaceutical Sciences. 2012;45(3):320-329. DOI: 10.1016/j.ejps.2011.11.017
  51. 51. Pozo-Guisado E, Centeno F, Merino JM, Mulero-navarro S, Jesu M, Alvarez-barrientos A, et al. Resveratrol-induced apoptosis in MCF-7 human breast cancer cells involves a caspase-independent mechanism with downregulation of Bcl-2 and NF-kB. International Journal of Cancer. 2005;115(1):74-84
  52. 52. Jones CB, Clements MK, Wasi S, Daoud SS. Enhancement of camptothecin-induced cytotoxicity with UCN-01 in breast cancer cells: Abrogation of S/G2 arrest. Cancer Chemotherapy and Pharmacology. 2000;45(3):252-258
  53. 53. Chu C, Xu J, Cheng D, Li X, Tong S, Yan J, et al. Anti-proliferative and apoptosis-inducing effects of camptothecin-20(s)-O-(2-pyrazolyl-1) acetic ester in human breast tumor MCF-7 cells. Molecules. 2014;19(4):4941-4955. DOI: 10.3390/molecules19044941
  54. 54. Ramachandran C, Rodriguez S, Ramachandran R, Nair PKR, Fonseca H, Khatib Z, et al. Expression profiles of apoptotic genes induced by curcumin in human breast cancer and mammary epithelial cell lines. Anticancer Research. 2005;25(5):3293-3302
  55. 55. Prasad CP, Rath G, Mathur S, Bhatnagar D, Ralhan R. Chemico-biological interactions potent growth suppressive activity of curcumin in human breast cancer cells: Modulation of Wnt/beta-catenin signaling. Chemico-Biological Interactions. 2009;181(2):263-271. DOI: 10.1016/j.cbi.2009.06.012
  56. 56. Groth-Pedersen L, Ostenfeld MS, Høyer-Hansen M, Nylandsted J, Jäättelä M. Vincristine induces dramatic lysosomal changes and sensitizes cancer cells to lysosome-destabilizing siramesine. Cancer Research. 2007;67(5):2217-2225
  57. 57. Lin H-Y, Lansing L, Merillon J-M, Davis FB, Tang H-Y, Shih A, et al. Integrin αVβ3 contains a receptor site for resveratrol. The FASEB Journal. 2006;20(10):1742-1744. DOI: 10.1096/fj.06-5743fje
  58. 58. Dong Z. Molecular mechanism of the chemopreventive effect of resveratrol. Mutation Research. 2003;524:145-150
  59. 59. Gambini J, Inglés M, Olaso G, Abdelaziz KM, Vina J, Borras C. Properties of resveratrol:In vitroandin vivostudies about metabolism, bioavailability, and biological effects in animal models and humans. Oxidative Medicine and Cellular Longevity. 2015;2015:837042. DOI: 10.1155/2015/837042
  60. 60. Nakagawa H, Kiyozuka Y, Uemura Y, Senzaki H, Shikata N, Hioki K, et al. Resveratrol inhibits human breast cancer cell growth and may mitigate the effect of linoleic acid, a potent breast cancer cell stimulator. Journal of Cancer Research and Clinical Oncology. 2001;127(4):258-264
  61. 61. Alkhalaf M. Resveratrol-induced growth inhibition in MDA-MB-231 breast cancer cells is associated with mitogen-activated protein kinase signaling and protein translation. European Journal of Cancer Prevention. 2007;16(4):334-341
  62. 62. Garvin S, Ollinger K, Dabrosin C. Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenograftsin vivo. Cancer Letters. 2006;231(1):113-122. DOI: 10.1016/j.canlet.2005.01.031
  63. 63. Cal C, Garban H, Jazirehi A, Yeh C, Mizutani Y, Bonavida B. Resveratrol and cancer: Chemoprevention, apoptosis, and chemo-immunosensitizing activities. Current Medicinal Chemistry. Anti-Cancer Agents. 2003;3(2):77-93
  64. 64. Ko J-H, Sethi G, Um J-Y, Shanmugam MK, Arfuso F, Alan Prem Kumar AB, et al. The role of resveratrol in cancer therapy. International Journal of Molecular Sciences. 2017;18(2589):1-36. DOI: 10.3390/ijms18122589
  65. 65. Bhat KP, Lantvit D, Christov K, Mehta RG, Moon RC, Pezzuto JM. Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models. Cancer Research. 2001;61(20):7456-7463
  66. 66. Provinciali M, Re F, Donnini A, Orlando F, Bartozzi B, Di Stasio G, et al. Effect of resveratrol on the development of spontaneous mammary tumors in HER-2/neutransgenic mice. International Journal of Cancer. 2005;115(1):36-45. DOI: 10.1002/ijc.20874
  67. 67. Banerjee S, Bueso-Ramos C, Aggarwal BB. Carcinogenesis in rats by resveratrol role of nuclear factor-kappa B, suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: Role of nuclear factor-kappa B, cyclooxygenase 2, and matrix metalloprotease 9. International Journal of Cancer. 2002;62(17):4945-4954
  68. 68. Chatterjee M, Chatterjee M, Das S, Janarthan M, Ramachandran HK. Role of 5-lipoxygenase in resveratrol mediated suppression of 7,12-dimethylbenz(α)anthracene-induced mammary carcinogenesis in rats. European Journal of Pharmacology. 2011;668:99-106. DOI: 10.1016/j.ejphar.2011.06.039
  69. 69. Nguyen AV, Martinez M, Stamos MJ, Moyer MP, Hope C, Holcombe RF. Results of a phase I pilot clinical trial examining the effect of plant-derived resveratrol and grape powder on Wnt pathway target gene expression in colonic mucosa and colon cancer. Cancer Management and Research. 2009;3(1):25-37
  70. 70. Berman AY, Motechin RA, Wiesenfeld MY, Holz MK. The therapeutic potential of resveratrol: A review of clinical trials. NPJ Precision Oncology. 2017;1:1-9. DOI: 10.1038/s41698-017-0038-6
  71. 71. Shanmugam MK, Rane G, Kanchi MM, Arfuso F, Chinnathambi A, Zayed ME, et al. The multifaceted role of Curcumin in cancer prevention and treatment. Molecules. 2015;20(2):2728-2769. DOI: 10.3390/molecules20022728
  72. 72. Liu H, Ho Y. Food science and human wellness anticancer effect of curcumin on breast cancer and stem cells. Food Science and Human Wellness. 2018;7(2):134-137. DOI: 10.1016/j.fshw.2018.06.001
  73. 73. Ravindran J, Prasad S, Aggarwal BB. Curcumin and cancer cells: How many ways can curry kill tumor cells selectively? The AAPS Journal. 2009;11(3):495-510. DOI: 10.1208/s12248-009-9128-x
  74. 74. Karunagaran D, Rashmi R, Kumar T. Induction of apoptosis by curcumin and its implications for cancer therapy. Current Cancer Drug Targets. 2005;5(2):117-129
  75. 75. Khan MA, Gahlot S, Majumdar S. Oxidative stress induced by curcumin promotes the death of cutaneous T-cell lymphoma (HuT-78) by disrupting the function of several molecular targets. Molecular Cancer Therapeutics. 2012;11(9):1873-1883. DOI: 10.1158/1535-7163
  76. 76. Chakraborty G, Jain S, Kale S, Raja R, Kumar S, Mishra R, et al. Curcumin suppresses breast tumor angiogenesis by abrogating osteopontin-induced VEGF expression. Molecular Medicine Reports. 2008;1(5):641-646. DOI: 10.3892/mmr_00000005
  77. 77. Kunnumakkara AB, Anand P, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Letters. 2008;269(2):199-225. DOI: 10.1016/j.canlet.2008.03.009
  78. 78. Hua W, Fu Y, Liao Y, Xia W, Chen Y, Zeng Y, et al. Curcumin induces down-regulation of EZH2 expression through the MAPK pathway in MDA-MB-435 human breast cancer cells. European Journal of Pharmacology. 2010;637(1-3):16-21. DOI: 10.1016/j.ejphar.2010.03.05179
  79. 79. Banerjee M, Singh P, Panda D. Curcumin suppresses the dynamic instability of microtubules, activates the mitotic checkpoint and induces apoptosis in MCF-7 cells. The FEBS Journal. 2010;277(16):3437-3448. DOI: 10.1111/j.1742-4658.2010.07750
  80. 80. Habli Z, Toumieh G, Fatfat M, Rahal ON, Gali-Muhtasib H. Emerging cytotoxic alkaloids in the battle against cancer: Overview of molecular mechanisms. Molecules. 2017;22(2):1-22. DOI: 10.3390/molecules22020250
  81. 81. Wink M. Modes of action of herbal medicines and plant secondary metabolites. Medicine. 2015;2(3):251-286. DOI: 10.3390/medicines2030251
  82. 82. Aniszewski T. Alkaloids. Secrets of Life. Alkaloid Chemistry, Biological Significance, Applications and Ecological Role.Amsterdam: Elsevier; 2007. p. 316
  83. 83. Mohan K, Jeyachandran R. Alkaloids as anticancer agents. Annals of Phytomedicine. 2012;1(1):46-53
  84. 84. Legarza K, Yang L. New molecular mechanisms of action of camptothecin-type drugs. Anticancer Research. 2006;26(5A):3301-3305
  85. 85. Sirikantaramas S, Yamazaki M, Saito K. Mutations in topoisomerase I as a self-resistance mechanism coevolved with the production of the anticancer alkaloid camptothecin in plants. Proceedings of the National Academy of Sciences of the United States of America. 2008;105(18):6782-6786. DOI: 10.1073/pnas.0801038105
  86. 86. Liu LF, Desai SD, Li TK, Mao Y, Sun M, Sim S. Mechanism of action of camptothecin. Annals of the New York Academy of Sciences. 2000;922:1-10
  87. 87. Burke TG, Xiang TX, Anderson BD, Latus LJ. Recent advances in camptothecin drug design and delivery strategies. camptothecins in cancer therapy. Human Press. 2005:171-190. DOI: 10.1385/1-59259-866-8:171
  88. 88. Giovanella BC, Hinz HR, Kozielski AJ, Stehlin JS, Silber R, Potmesil M. Complete growth inhibition of human cancer inhibition of human cancer xenografts in nude mice by treatment with 20-(5-camptothecin). Cancer Research. 1991;5:3052-3056
  89. 89. Venditto VJ, Simanek EE. Cancer therapies utilizing the camptothecins: A review ofin vivoliterature. Molecular Pharmaceutics. 2010;7(2):307-349. DOI: 10.1021/mp900243b
  90. 90. Lee C, Huang Y, Yang C, Huang K. Drug delivery systems and combination therapy by using vinca alkaloids. Current Topics in Medicinal Chemistry. 2015;15(15):1491-1500. DOI: 10.2174/1568026615666150414120547
  91. 91. Moudi M, Go R, Yien CY, Nazre M. Vinca alkaloids. International Journal of Preventive Medicine. 2013;4(11):1231-1235
  92. 92. Downing KH. Structural basis for the interaction of tubulin with proteins and drugs that affect microtubule dynamics. Annual Review of Cell and Developmental Biology. 2000;16:89-111
  93. 93. Gregory RK, Smith IE. Vinorelbina: A clinical review. British Journal of Cancer. 2000;82:1907-1913
  94. 94. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, et al. Erratum: Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. The Journal of Clinical Investigation. 2000;105:R15-R24. DOI: 10.1172/JCI08829C1
  95. 95. Sen K, Mandal M. Second generation liposomal cancer therapeutics: Transition from laboratory to clinic. International Journal of Pharmaceutics. 2013;448(1):28-43. DOI: 10.1016/j.ijpharm.2013.03.006
  96. 96. Allen TM, Cullis PR. Liposomal drug delivery systems: From concept to clinical applications. Advanced Drug Delivery Reviews. 2013;65(1):36-48. DOI: 10.1016/j.addr.2012.09.037
  97. 97. Shaban N, Abdel-Rahman S, Haggag A, Awad D, Bassiouny A, Talaat I. Combination between Taxol-encapsulated liposomes and Eruca sativa seed extract suppresses mammary tumors in female rats induced by 7,12-dimethylbenz(α)anthracene. Asian Pacific Journal of Cancer Prevention. 2016;17(1):117-123
  98. 98. Singh B, Shoulson R, Chatterjee A, Ronghe A, Bhat NK, Dim DC, et al. Resveratrol inhibits estrogen-induced breast carcinogenesis through induction of NRF2-mediated protective pathways. Carcinogenesis. 2014;35(8):1872-1880. DOI: 10.1093/carcin/bgu120
  99. 99. Zhou QM, Wang XF, Liu XJ, Zhang H, Lu YY, Su SB. Curcumin enhanced antiproliferative effect of mitomycin C in human breast cancer MCF-7 cellsin vitroandin vivo. Acta Pharmacologica Sinica. 2011;32(11):1402-1410. DOI: 10.1038/aps.2011.97
  100. 100. Camacho KM, Kumar S, Menegatti S, Vogus DG, Anselmo AC, Mitragotri S. Synergistic Antitumor Activity of Camptothecin-Doxorubicin Combinations and their Conjugates with Hyaluronic Acid. Journal of Controlled Release. 2015:1-25. DOI:10.1016/j.jconrel.2015.04.031
  101. 101. Ping M, Russell M. Paclitaxel Nano-delivery systems: A comprehensive review. Journal of Nanomedicine & Nanotechnology. 2013;4(2):1000164. DOI: 10.4172/2157-7439.1000164
  102. 102. Sofias AM, Dunne M, Storm G, Allen G. The battle of “nano” paclitaxel. Advanced Drug Delivery Reviews. 2017;122:20-30. DOI: 10.1016/j.addr.2017.02.003
  103. 103. Wu C, Gao Y, Liu Y, Xu X. Pure paclitaxel nanoparticles: Preparation, characterization, and antitumor effect for human liver cancer SMMC-7721 cells. International Journal of Nanomedicine. 2018;13:6189-6198. DOI: 10.2147/IJN.S169209
  104. 104. Wang F, Porter M, Konstantopoulos A, Zhang P, Cui H. Preclinical development of drug delivery systems for paclitaxel-based cancer chemotherapy. Journal of Controlled Release. 2017;267:100-118. DOI: 10.1016/j.jconrel.2017.09.026
  105. 105. Shen J, Sun H, Xu P, Yin Q , Zhang Z, Wang S, et al. Biomaterials simultaneous inhibition of metastasis and growth of breast cancer by co-delivery of twist shRNA and paclitaxel using pluronic P85-PEI/TPGS complex nanoparticles. Biomaterials. 2012;34(5):1581-1590. DOI: 10.1016/j.biomaterials.2012.10.057
  106. 106. Mahalingam M, Krishnamoorthy K. Selection of a suitable method for the preparation of polymeric nanoparticles: Multi-criteria decision making approach. Advanced Pharmaceutical Bulletin. 2015;5(1):57-67. DOI: 10.5681/apb.2015.008
  107. 107. Acevedo-Morantes CY, Acevedo-Morantes MT, Suleiman-Rosado D, Ramírez-Vick JE. Evaluation of the cytotoxic effect of camptothecin solid lipid nanoparticles on MCF7 cells. Drug Delivery. 2013;20(8):338-348. DOI: 10.3109/10717544.2013.834412
  108. 108. Mohanty C, Sahoo SK. Thein vitrostability andin vivopharmacokinetics of curcumin prepared as an aqueous nanoparticulate formulation. Biomaterials. 2010;31(25):6597-6611. DOI: 10.1016/j.biomaterials.2010.04.062
  109. 109. Manikandan M, Kannan K. Pharmacokinetic and pharmacodynamic evaluation of camptothecin encapsulated poly (methacylic acid-co-methyl methacrylate) nanoparticles. Journal of Applied Pharmaceutical Science. 2017;7(3):9-16. DOI: 10.7324/JAPS.2017.70303
  110. 110. Mulik RS, Mönkkönen J, Juvonen RO, Mahadik KR, Paradkar AR. Transferrin mediated solid lipid nanoparticles containing curcumin: Enhancedin vitroanticancer activity by induction of apoptosis. International Journal of Pharmaceutics. 2010;398(1-2):190-203. DOI: 10.1016/j.ijpharm.2010.07.021
  111. 111. Tang H, Murphy CJ, Zhang B, Shen Y, Van Kirk EA, Murdoch WJ, et al. Biomaterials Curcumin polymers as anticancer conjugates. Biomaterials. 2010;31(27):7139-7149. DOI: 10.1016/j.biomaterials.2010.06.007
  112. 112. Ducry L, Stump B. Antibody—Drug conjugates: Linking cytotoxic payloads to monoclonal antibodies. Bioconjugate Chemistry. 2010;21:5-13. DOI: 10.1021/bc9002019

Written By

Elvia Pérez-Soto, Cynthia Carolina Estanislao-Gómez, David Guillermo Pérez-Ishiwara, Crisalde Ramirez-Celis and María del Consuelo Gómez-García

Submitted: January 30th, 2019 Reviewed: May 31st, 2019 Published: August 6th, 2019